Dear Katie

I am writing on behalf of the British Association of Urological Surgeons, Section of Oncology. Our only comment on the ACD is that we think there should be guidance on the ongoing treatment after castrate testosterone is achieved using Degarelix - whether patients should continue Degarelix or be switched to an LHRH analogue in the interests of cost saving?

Your sincerely

[redacted]
BAUS
[redacted]
Website: www.baus.org.uk

The BAUS website includes a section dedicated to information for patients – please go to www.baus.org.uk/patients

The British Association of Urological Surgeons Limited registered in England and Wales
Registered Charity No: 1127044
Registered Company No: 06054614